{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:52:06Z","timestamp":1793490726117,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T00:00:00Z","timestamp":1450656000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s40261-015-0361-z","type":"journal-article","created":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T14:45:25Z","timestamp":1450709125000},"page":"177-194","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Efficacy and Safety of Ferric Carboxymaltose and Other Formulations in Iron-Deficient Patients: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials"],"prefix":"10.1007","volume":"36","author":[{"given":"Carla","family":"Rognoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Meregaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania","family":"Marmifero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Tarricone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,21]]},"reference":[{"issue":"4","key":"361_CR1","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1017\/S1368980008002401","volume":"12","author":"E McLean","year":"2009","unstructured":"McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993\u20132005. Public Health Nutr. 2009;12(4):444\u201354.","journal-title":"Public Health Nutr."},{"key":"361_CR2","unstructured":"WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. World Health Organization, Geneva (WHO\/NMH\/NHD\/MNM\/11.1) (2011). http:\/\/www.who.int\/vmnis\/indicators\/haemoglobin\/en . Accessed 30th October 2015."},{"issue":"3","key":"361_CR3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ajh.20249","volume":"78","author":"J Umbreit","year":"2005","unstructured":"Umbreit J. Iron deficiency: a concise review. Am J Hematol. 2005;78(3):225\u201331.","journal-title":"Am J Hematol."},{"issue":"3","key":"361_CR4","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.tmrv.2014.05.001","volume":"28","author":"A Shander","year":"2014","unstructured":"Shander A, Goodnough LT, Javidroozi M, Auerbach M, Carson J, Ershler WB, et al. Iron deficiency anemia: bridging the knowledge and practice gap. Transfus Med Rev. 2014;28(3):156\u201366.","journal-title":"Transfus Med Rev."},{"issue":"2","key":"361_CR5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/MEG.0b013e32834f3140","volume":"24","author":"K Liu","year":"2012","unstructured":"Liu K, Kaffes AJ. Iron deficiency anaemia: a review of diagnosis, investigation and management. Eur J Gastroenterol Hepatol. 2012;24(2):109\u201316.","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"12","key":"361_CR6","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2011-04-346304","volume":"118","author":"PA Krayenbuehl","year":"2011","unstructured":"Krayenbuehl PA, Battegay E, Breymann C, et al. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritinconcentration. Blood. 2011;118(12):3222\u20137.","journal-title":"Blood."},{"issue":"2","key":"361_CR7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.23354","volume":"88","author":"DB Bregman","year":"2013","unstructured":"Bregman DB, Morris D, Koch TA, He A, Goodnough LT. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Haematol. 2013;88(2):97\u2013101. doi: 10.1002\/ajh.23354 .","journal-title":"Am J Haematol."},{"key":"361_CR8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1542-4758.2009.00409.x","volume":"14","author":"GR Bailie","year":"2010","unstructured":"Bailie GR, Mason NA, Valaoras TG. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Hemodial Int. 2010;14:47\u201354.","journal-title":"Hemodial Int"},{"issue":"1","key":"361_CR9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijgo.2007.10.009","volume":"101","author":"C Breymann","year":"2008","unstructured":"Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet. 2008;101(1):67\u201373.","journal-title":"Int J Gynaecol Obstet."},{"issue":"3","key":"361_CR10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/bja\/aer242","volume":"107","author":"E Bisbe","year":"2011","unstructured":"Bisbe E, Garc\u00eda-Erce JA, D\u00edez-Lobo AI, Mu\u00f1oz M. Anaemia Working Group Espa\u00f1a. A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery. Br J Anaesth. 2011;107(3):477\u20138.","journal-title":"Br J Anaesth."},{"issue":"1","key":"361_CR11","first-page":"8","volume":"10","author":"M Mu\u00f1oz","year":"2012","unstructured":"Mu\u00f1oz M, Garc\u00eda-Erce JA, Cuenca J, Bisbe E, Naveira E, AWGE (Spanish Anaemia Working Group). On the role of iron therapy for reducing allogeneic blood transfusion in orthopaedic surgery. Blood Transfus. 2012;10(1):8\u201322.","journal-title":"Blood Transfus."},{"key":"361_CR12","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/asheducation-2010.1.338","volume":"2010","author":"M Auerbach","year":"2010","unstructured":"Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematol Am Soc Hematol Educ Program. 2010;2010:338\u201347.","journal-title":"Hematol Am Soc Hematol Educ Program."},{"issue":"2","key":"361_CR13","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/trf.12289","volume":"54","author":"JE Onken","year":"2014","unstructured":"Onken JE, Bregman DB, Harrington RA, Morris D, Acs P, Akright B, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion. 2014;54(2):306\u201315.","journal-title":"Transfusion."},{"key":"361_CR14","unstructured":"http:\/\/www.products.sanofi-aventis.us\/ferrlecit\/ferrlecit.pdf . Accessed 30th October 2015."},{"key":"361_CR15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2326-11-4","volume":"11","author":"RA Moore","year":"2011","unstructured":"Moore RA, Gaskell H, Rose P, et al. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord. 2011;11:4.","journal-title":"BMC Blood Disord."},{"issue":"5","key":"361_CR16","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336\u201341.","journal-title":"Int J Surg"},{"key":"361_CR17","volume-title":"Methods for meta-analysis in medical research","author":"AJ Sutton","year":"2000","unstructured":"Sutton AJ, Abrams KR, Jones DR, et al. Methods for meta-analysis in medical research. London: Wiley; 2000."},{"key":"361_CR18","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1524-4733.2008.00347.x","volume":"11","author":"JP Jansen","year":"2008","unstructured":"Jansen JP, Crawford B, Bergman G, Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health. 2008;11:956\u201364.","journal-title":"Value Health"},{"issue":"6","key":"361_CR19","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683\u201391.","journal-title":"J Clin Epidemiol."},{"key":"361_CR20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3:80\u201397.","journal-title":"Res Synth Methods."},{"key":"361_CR21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","volume":"14","author":"JP Jansen","year":"2011","unstructured":"Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health. 2011;14:417\u201328.","journal-title":"Value Health"},{"key":"361_CR22","doi-asserted-by":"crossref","first-page":"e11054","DOI":"10.1371\/journal.pone.0011054","volume":"5","author":"S Donegan","year":"2010","unstructured":"Donegan S, Williamson P, Gamble C, Tudur-Smith C. Indirect comparisons: a review of reporting and methodological quality. PLoS One. 2010;5:e11054.","journal-title":"PLoS One"},{"key":"361_CR23","doi-asserted-by":"crossref","first-page":"b1147","DOI":"10.1136\/bmj.b1147","volume":"338","author":"F Song","year":"2009","unstructured":"Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ. 2009;338:b1147.","journal-title":"BMJ"},{"key":"361_CR24","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105\u201324.","journal-title":"Stat Med"},{"key":"361_CR25","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1008929526011","volume":"10","author":"DJ Lunn","year":"2000","unstructured":"Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS\u2014a Bayesian modelling framework: concepts, structure and extensibility. Stat Comput. 2000;10:325\u201337.","journal-title":"Stat Comput"},{"issue":"2","key":"361_CR26","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.sleep.2007.12.006","volume":"10","author":"CJ Earley","year":"2009","unstructured":"Earley CJ, Horsk\u00e1 A, Mohamed MA, Barker PB, Beard JL, Allen RP. A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med. 2009;10(2):206\u201311.","journal-title":"Sleep Med."},{"issue":"1","key":"361_CR27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1523-1755.2003.00703.x","volume":"63","author":"DW Coyne","year":"2003","unstructured":"Coyne DW, Adkinson NF, Nissenson AR, Fishbane S, Agarwal R, Eschbach JW, Michael B, Folkert V, Batlle D, Trout JR, Dahl N, Myirski P, Strobos J, Warnock DG, Ferlecit Investigators. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int. 2003;63(1):217\u201324.","journal-title":"Kidney Int."},{"key":"361_CR28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/ndt\/gft251","volume":"29","author":"JE Onken","year":"2014","unstructured":"Onken JE, Bregman DB, Harrington RA. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transpl. 2014;29:833\u201342.","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"361_CR29","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000096174","volume":"26","author":"R Agarwal","year":"2006","unstructured":"Agarwal R, Rizkala AR, Bastani B, et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol. 2006;26(5):445\u201354.","journal-title":"Am J Nephrol."},{"issue":"2","key":"361_CR30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/apt.12556","volume":"39","author":"P Bager","year":"2014","unstructured":"Bager P, Dahlerup JF. Randomised clinical trial: oral vs. intravenous iron after upper gastrointestinal haemorrhage. A placebo-controlled study. Aliment Pharmacol Ther. 2014;39(2):176\u201387.","journal-title":"Aliment Pharmacol Ther."},{"key":"361_CR31","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1053\/j.gastro.2011.06.005","volume":"141","author":"R Evstatiev","year":"2011","unstructured":"Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor: a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141:846\u201353.","journal-title":"Gastroenterology"},{"key":"361_CR32","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/j.1572-0241.2007.01744.x","volume":"103","author":"S Kulnigg","year":"2008","unstructured":"Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008;103:1182\u201392.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"361_CR33","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1097\/MIB.0b013e318281f4db","volume":"19","author":"S Kulnigg-Dabsch","year":"2013","unstructured":"Kulnigg-Dabsch S, Schmid W, Howaldt S, et al. Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial. Inflamm Bowel Dis. 2013;19(8):1609\u201316.","journal-title":"Inflamm Bowel Dis."},{"issue":"5","key":"361_CR34","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/ndt\/gfq613","volume":"26","author":"WY Qunibi","year":"2011","unstructured":"Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011;26(5):1599\u2013607.","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"361_CR35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.atherosclerosissup.2012.10.012","volume":"14","author":"U Schatz","year":"2013","unstructured":"Schatz U, Arneth B, Siegert G, et al. Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations. Atheroscler Suppl. 2013;14(1):115\u201322.","journal-title":"Atheroscler Suppl."},{"key":"361_CR36","doi-asserted-by":"crossref","unstructured":"Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol 2008;199(4):435.e1\u20137.","DOI":"10.1016\/j.ajog.2008.07.046"},{"issue":"17","key":"361_CR37","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jacc.2007.07.029","volume":"50","author":"JE Toblli","year":"2007","unstructured":"Toblli JE, Lombra\u00f1a A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50(17):1657\u201365.","journal-title":"J Am Coll Cardiol."},{"key":"361_CR38","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.AOG.0000275286.03283.18","volume":"110","author":"DB Wyck Van","year":"2007","unstructured":"Van Wyck DB, Martens MG, Seid MH, et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia. A randomized controlled trial. Obstet Gynecol. 2007;110:267\u201378.","journal-title":"Obstet Gynecol."},{"issue":"12","key":"361_CR39","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1111\/j.1537-2995.2009.02327.x","volume":"49","author":"DB Wyck Van","year":"2009","unstructured":"Van Wyck DB, Mangione A, Morrison J, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49(12):2719\u201328.","journal-title":"Transfusion."},{"issue":"4","key":"361_CR40","doi-asserted-by":"crossref","first-page":"e94217","DOI":"10.1371\/journal.pone.0094217","volume":"9","author":"B Favrat","year":"2014","unstructured":"Favrat B, Balck K, Breymann C, Hedenus M, Keller T, Mezzacasa A, Gasche C. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women-PREFER a randomized, placebo-controlled study. PLoS One. 2014;9(4):e94217.","journal-title":"PLoS One."},{"issue":"10","key":"361_CR41","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/mds.22562","volume":"24","author":"L Grote","year":"2009","unstructured":"Grote L, Leissner L, Hedner J, Ulfberg J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov Disord. 2009;24(10):1445\u201352.","journal-title":"Mov Disord."},{"key":"361_CR42","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.cgh.2012.10.013","volume":"11","author":"R Evstatiev","year":"2013","unstructured":"Evstatiev R, Alexeeva O, Bokemeyer B, et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:269\u201377.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"6","key":"361_CR43","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2165\/00003495-200969060-00007","volume":"69","author":"KA Lyseng-Williamson","year":"2009","unstructured":"Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009;69(6):739\u201356.","journal-title":"Drugs."},{"issue":"1","key":"361_CR44","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40265-014-0332-3","volume":"75","author":"GM Keating","year":"2015","unstructured":"Keating GM. Ferric carboxymaltose: a review of its use in iron deficiency. Drugs. 2015;75(1):101\u201327.","journal-title":"Drugs."},{"issue":"2","key":"361_CR45","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/2040620714521127","volume":"5","author":"DB Bregman","year":"2014","unstructured":"Bregman DB, Goodnough LT. Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia. Ther Adv Hematol. 2014;5(2):48\u201360.","journal-title":"Ther Adv Hematol."},{"issue":"1","key":"361_CR46","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/bja\/aes139","volume":"109","author":"A Shander","year":"2012","unstructured":"Shander A, Van Aken H, Colomina MJ, Gombotz H, Hofmann A, Krauspe R, et al. Patient blood management in Europe. Br J Anaesth. 2012;109(1):55\u201368.","journal-title":"Br J Anaesth."},{"issue":"7","key":"361_CR47","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3111\/13696998.2015.1029491","volume":"18","author":"T Hofmarcher","year":"2015","unstructured":"Hofmarcher T, Borg S. Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden. J Med Econ. 2015;18(7):492\u2013501.","journal-title":"J Med Econ."},{"issue":"10","key":"361_CR48","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.recesp.2014.10.011","volume":"68","author":"J Com\u00edn-Colet","year":"2015","unstructured":"Com\u00edn-Colet J, Rubio-Rodr\u00edguez D, Rubio-Terr\u00e9s C, Enjuanes-Grau C, Gutzwiller FS, Anker SD, Ponikowski P. A cost-effectiveness analysis of ferric carboxymaltose in patients with iron deficiency and chronic heart failure in Spain. Rev Esp Cardiol (Engl Ed). 2015;68(10):846\u201351.","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"issue":"7","key":"361_CR49","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/eurjhf\/hfs083","volume":"14","author":"FS Gutzwiller","year":"2012","unstructured":"Gutzwiller FS, Schwenkglenks M, Blank PR, Braunhofer PG, Mori C, Szucs TD, et al. Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK. Eur J Heart Fail. 2012;14(7):782\u201390.","journal-title":"Eur J Heart Fail."},{"issue":"12","key":"361_CR50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1478-7547-12-19","volume":"10","author":"EA Lim","year":"2014","unstructured":"Lim EA, Sohn HS, Lee H, Choi SE. Cost-utility of ferric carboxymaltose (Ferinject\u00ae) for iron-deficiency anemia patients with chronic heart failure in South Korea. Cost Eff Resour Alloc. 2014;10(12):19.","journal-title":"Cost Eff Resour Alloc."},{"issue":"Suppl 4","key":"361_CR51","first-page":"108S","volume":"109","author":"SS Gordon","year":"2007","unstructured":"Gordon SS, Hadley PE, Van Wyck DB, et al. Iron carboxymaltose, a new intravenous iron agent for iron deficiency anemia in heavy uterine bleeding. Obstet Gynecol. 2007;109(Suppl 4):108S.","journal-title":"Obstet Gynecol."},{"key":"361_CR52","first-page":"99","volume":"93","author":"C Rognoni","year":"2015","unstructured":"Rognoni C, Tarricone R, Meregaglia M. Impatto economico dell\u2019utilizzo di carbossimaltosio ferrico in pazienti con anemia da carenza di ferro nelle regioni italiane. MECOSAN. Manag Econ Sanit. 2015;93:99\u2013114.","journal-title":"Manag Econ Sanit"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0361-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-015-0361-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0361-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T07:30:40Z","timestamp":1718263840000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-015-0361-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,21]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["361"],"URL":"https:\/\/doi.org\/10.1007\/s40261-015-0361-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,21]]}}}